外周艾塞那肽(exendin-4)对啮齿动物的抗肥胖作用:对摄食量、体重、代谢状态的影响及副作用措施。

文章的细节

引用

Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA

外周艾塞那肽(exendin-4)对啮齿动物的抗肥胖作用:对摄食量、体重、代谢状态的影响及副作用措施。

Int J Obes(伦敦)。2006年9月,30(9):1332 - 40。Epub 2006 3月14日。

PubMed ID
16534527 (PubMed视图
摘要

背景:Exenatide (exendin-4)是一种肠促胰岛素模拟药,目前作为一种用于2型糖尿病患者的抗糖尿病药物上市。在临床前模型中,在低脂喂养、瘦素受体缺乏的啮齿动物中也显示出体重的减轻。目的:为了更紧密地模拟人类肥胖的多基因和环境状态,我们研究了艾塞那肽对高脂肪喂养的正常(瘦素信号系统完整的)啮齿动物的食物摄入量和体重的影响。由于胰高血糖素样肽-1受体激动已被发现诱发啮齿动物内脏疾病相关的行为,我们还研究了外周艾塞那肽对高岭土消耗和运动活动的影响。方法与结果:高脂喂养的C57BL/6小鼠和Sprague-Dawley大鼠经皮下植入渗透泵给予艾塞那肽(3,10和30微克/公斤/天)治疗4周。每周评估食物摄入量和体重。第4周时,测量体成分和血浆代谢情况。在单次腹腔注射艾塞那肽(0.1-10微克/公斤)后,测定了禁食sd大鼠的高岭土摄入量和运动活动。艾塞那肽治疗小鼠和大鼠的摄取量和体重呈剂量依赖性降低;在10和30微克/公斤/天的治疗期间,观察到体重增加显著减少(P<0.05)。 Decreased body weight gain was associated with a significant decrease in fat mass (P<0.05) with sparing of lean tissue. Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05). Exenatide at 10 microg/kg significantly reduced food intake (P<0.05) but failed to induce kaolin intake. In general, locomotor activity was reduced at doses of exenatide that decreased food intake, although a slightly higher dose was required to produce significant changes in activity. CONCLUSION: Systemic exenatide reduces body weight gain in normal, high-fat-fed rodents, a model that parallels human genetic variation and food consumption patterns, and may play a role in metabolic pathways mediating food intake.

beplay体育安全吗引用本文的药物库数据

药物靶点
药物 目标 种类 生物 药理作用 行动
Exenatide 胰高血糖素样肽1受体 蛋白质 人类
是的
受体激动剂
细节